Identification of Risk Factors for Requiring Transfusion during Front-Line Chemotherapy for Ovarian Cancer

Abstract

Objective. Anemia requiring red blood cell (RBC) transfusion is common in ovarian cancer (OC) patients receiving post-debulking surgery chemotherapy. Erythropoietin use has been shown to decrease transfusion requirements in patients receiving chemotherapy. We sought to identify pretreatment risk factors that could identify patients at increased risk for requiring RBC transfusion during first-line treatment for ovarian cancer.Methods. One hundred seventy-five consecutive patients who received chemotherapy with either carboplatin–paclitaxel or cisplatin–paclitaxel following debulking surgery for epithelial OC from 1993 to 1996 were identified. No patient received erythropoietin. Patient characteristics recorded included: age, stage, prechemotherapy hemoglobin, nadir hemoglobin, number of cycles and doses of chemotherapy received. The outcome was requiring RBC transfusion. Independent predictors of requiring RBC transfusion were identified using multivariate analyses.Results. Median age of the cohort was 62 years (range, 28–86). Seventy-one and four-tenths percent had FIGO stage III/IV disease. Median prechemotherapy hemoglobin was 11 g/dL (range, 7.1–15.4); median nadir hemoglobin was 9.3 g/dL (range, 6.6–11.1). One hundred nineteen (66%) patients received cisplatin–paclitaxel, and 61 (34%) received carboplatin–paclitaxel. Of 175 patients, 31 (18%, 95% CI = 12–23%) required RBC transfusion. Independent risk factors for RBC transfusion were prechemotherapy hemoglobin <10 g/dL (P < 0.01, odds ratio = 3.78, 95% CI = 1.52–9.44) and carboplatin–paclitaxel versus cisplatin–paclitaxel treatment (P = 0.01, odds ratio = 3.14, 95% CI = 1.27–7.76). Of 175 patients, 40 (22.8%) had a prechemotherapy hemoglobin <10 g/dL. Fifty percent of patients with prechemotherapy hemoglobin <10 g/dL who received carboplatin–paclitaxel required RBC transfusion, compared with 7.7% of patients with hemoglobin >10 g/dL who received cisplatin–paclitaxel.Conclusion. Ovarian cancer patients frequently require RBC transfusion during postdebulking platinum–paclitaxel chemotherapy. Patients with prechemotherapy hemoglobin <10 g/dL and those receiving carboplatin–paclitaxel are at increased risk of requiring RBC transfusion. Early initiation of erythropoietin use in such patients may reduce transfusion needs.